Molecular detection of prostate cancer in urine by GSTP1 hypermethylation - PubMed (original) (raw)

Affiliations

PMID: 11555585

Molecular detection of prostate cancer in urine by GSTP1 hypermethylation

P Cairns et al. Clin Cancer Res. 2001 Sep.

Abstract

Novel approaches for the early detection and management of prostate cancer are urgently needed. Clonal genetic alterations have been used as targets for the detection of neoplastic cells in bodily fluids from many cancer types. A similar strategy for molecular diagnosis of prostate cancer requires a common and/or early genetic alteration as a specific target for neoplastic prostate cells. Hypermethylation of regulatory sequences at the glutathione S-transferase pi (GSTP1) gene locus is found in the majority (>90%) of primary prostate carcinomas, but not in normal prostatic tissue or other normal tissues. We hypothesized that urine from prostate cancer patients might contain shed neoplastic cells or debris amenable to DNA analysis. Matched specimens of primary tumor, peripheral blood lymphocytes (normal control), and simple voided urine were collected from 28 patients with prostate cancer of a clinical stage amenable to cure. Genomic DNA was isolated from the samples, and the methylation status of GSTP1 was examined in a blinded manner using methylation-specific PCR. Decoding of the results revealed that 22 of 28 (79%) prostate tumors were positive for GSTP1 methylation. In 6 of 22 (27%) cases, the corresponding urine-sediment DNA was positive for GSTP1 methylation, indicating the presence of neoplastic DNA in the urine. Furthermore, there was no case where urine-sediment DNA harbored methylation when the corresponding tumor was negative. Although we only detected GSTP1 methylation in under one-third of voided urine samples, we have demonstrated that molecular diagnosis of prostate neoplasia in urine is feasible. Larger studies focusing on carcinoma size, location in the prostate, and urine collection techniques, as well as more sensitive technology, may lead to the useful application of GSTP1 hypermethylation in prostate cancer diagnosis and management.

PubMed Disclaimer

Cited by

Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA.
Tetzner R, Dietrich D, Distler J. Tetzner R, et al. Nucleic Acids Res. 2007;35(1):e4. doi: 10.1093/nar/gkl955. Epub 2006 Nov 28. Nucleic Acids Res. 2007. PMID: 17135186 Free PMC article.
LogLoss-BERAF: An ensemble-based machine learning model for constructing highly accurate diagnostic sets of methylation sites accounting for heterogeneity in prostate cancer.
Babalyan K, Sultanov R, Generozov E, Sharova E, Kostryukova E, Larin A, Kanygina A, Govorun V, Arapidi G. Babalyan K, et al. PLoS One. 2018 Nov 2;13(11):e0204371. doi: 10.1371/journal.pone.0204371. eCollection 2018. PLoS One. 2018. PMID: 30388122 Free PMC article.
Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer.
Thuret R, Chantrel-Groussard K, Azzouzi AR, Villette JM, Guimard S, Teillac P, Berthon P, Houlgatte A, Latil A, Cussenot O. Thuret R, et al. Br J Cancer. 2005 Jan 31;92(2):236-40. doi: 10.1038/sj.bjc.6602311. Br J Cancer. 2005. PMID: 15655554 Free PMC article.

Molecular detection of prostate cancer in urine by GSTP1 hypermethylation - PubMed (original) (raw)